Gut Microbiota in Liver Metastasis of Small Cell Lung Cancer
A NEW review has highlighted the gut microbiota as a potential systemic driver of liver metastasis in small cell lung cancer, shifting attention beyond tumor genetics alone to the gut liver axis. The authors describe liver metastasis in small cell lung cancer as a major clinical challenge associated with poor outcomes, transient benefit from chemoimmunotherapy, and limited treatment options. They argue that microbial dysbiosis may help create a permissive hepatic environment that supports metastatic seeding, immune escape, and resistance to treatment.
According to the review, dysbiosis may disrupt intestinal barrier integrity and increase translocation of microbial products into portal circulation. This includes lipopolysaccharide and other inflammatory signals that reach the liver directly. Once there, these factors may chronically activate Kupffer cells and alter immune tolerance, shifting the liver from a protective filter to a pro metastatic niche. The review also outlines how this process may recruit myeloid derived suppressor cells, expand regulatory T cells, and weaken anti-tumor surveillance against circulating small cell lung cancer cells.
Mechanisms Linking the Gut Liver Axis and Metastatic Growth
The authors further propose that microbial metabolites contribute to liver remodeling in ways that favor metastatic outgrowth. Secondary bile acids such as deoxycholic acid are described as key mediators that may activate hepatic stellate cells, promote extracellular matrix deposition, and drive fibrosis. This stiffened, growth supportive microenvironment may then enhance tumor cell survival, angiogenesis, and colonization. By contrast, beneficial short chain fatty acids such as butyrate are presented as potentially protective through anti-inflammatory and anti-fibrotic effects.
Therapeutic Implications for Clinical Practice
The review concludes that microbiota directed approaches could eventually complement standard treatment in this setting. Potential strategies include probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and next generation microbial therapeutics. The authors also note the importance of avoiding unnecessary antibiotic exposure near immunotherapy and suggest that future studies should focus on functional microbial biomarkers, mechanistic validation, and combination trials in patients with liver metastatic small cell lung cancer. While the evidence remains largely translational and hypothesis generating, the review positions the gut microbiota as a promising target in a disease with few durable options.
Reference
Xiao Y et al. The role of gut microbiota in liver metastasis of small cell lung cancer: mechanisms and therapeutic implications. Front Cell Infect Microbiol. 2026;16:10.3389/fcimb.2026.1767998.
